From 24/7 Wall St. · Alex Sirois · · 1m 10s
Eli Lilly's Tough Month: Bank Predicts 37% Gains
Citi forecasts 37% stock gains for Eli Lilly as selloff ends.
In brief
Citi forecasts 37% stock gains for Eli Lilly as selloff ends. Citi predicts Eli Lilly's stock could rise 37% by year-end due to obesity drug pipeline advancements. Originally reported by 24/7 Wall St..
Eli Lilly's Q2 Results Crush Estimates
Eli Lilly's Q2 revenue beat consensus by 11.06% and EPS came in 27.27% above estimates.
Stock Drops 7.21% Despite Strong Results
Lilly shares dropped 7.21% over the past month, sliding from $1,255.40 to current levels.
Wall Street's Price Target Gap
Eli Lilly trades at $1,164.79 versus Wall Street's average target of $1,325.39, leaving 14% implied upside.
Citi's 37% Upside Case
Citi's Geoff Meacham targets $1,600 for Eli Lilly, implying 37% gains from current levels.
Obesity Market Dominance
Lilly dominates the GLP-1 obesity and diabetes market with Mounjaro and Zepbound generating $14.9 billion quarterly.
Pricing Pressures on Lilly
Realized U.S. prices fell 9% excluding rebates, and international pricing compressed after Mounjaro's inclusion in China's National Reimbursement Drug List.
Citi's Bull Case for 2027
Citi expects retatrutide to clear FDA by Q1 2027, with Foundayo maintaining inflection and Medicare Bridge Program expanding access.
The one thing
Citi predicts Eli Lilly's stock could rise 37% by year-end due to obesity drug pipeline advancements.
